BiotechTube

DS-8201a + Physician's Choice

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm, Gastrointestinal

Conditions

Neoplasm, Gastrointestinal

Trial Timeline

Nov 2, 2017 → Dec 11, 2020

NCT ID
NCT03329690

About DS-8201a + Physician's Choice

DS-8201a + Physician's Choice is a phase 2 stage product being developed by Daiichi Sankyo for Neoplasm, Gastrointestinal. The current trial status is completed. This product is registered under clinical trial identifier NCT03329690. Target conditions include Neoplasm, Gastrointestinal.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasm, Gastrointestinal were approved

Approved (20) Terminated (3) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03329690Phase 2Completed

Competing Products

20 competing products in Neoplasm, Gastrointestinal

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
LY2780301Eli LillyPhase 1
29
PemetrexedEli LillyPhase 2
35
pemetrexed + cisplatinEli LillyPhase 1/2
32
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Abemaciclib + ClarithromycinEli LillyPhase 1
29
Abemaciclib + FulvestrantEli LillyPhase 2
27
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
29
LY2784544Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35